Latest Capricor Therapeutics News & Updates

See the latest news and media coverage for Capricor. We track all announcements, press releases, and industry mentions in real time, all in one place.

Capricor Therapeutics (Capricor)

Biotechnology company developing cell and exosome-based therapeutics

capricor.com

Headquarters: San Diego, United States
Founded year: 2005
Company type: Public company
Number of employees: 50–300
Industry: Pharmaceuticals

Last updated Today

Latest news about Capricor Therapeutics (Capricor)

In short: Capricor Therapeutics shares plummeted after an FDA advisory committee voted 9-3 against the effectiveness of its DMD therapy, Deramiocel.

Company announcements

July 29 Capricor

Capricor announces publication of HOPE-3 data in The Lancet

The peer-reviewed results show a 54% slowing of upper limb decline and cardiac benefit in Duchenne patients.

July 27 Capricor

Capricor provides update on FDA advisory meeting for Deramiocel

Capricor responds to FDA briefing materials, highlighting HOPE-3 trial results and statistical plan differences ahead of the July 29 advisory committee meeting.

June 26 Capricor

Capricor announces FDA advisory committee meeting for Deramiocel

The meeting is on July 29, 2026, and the PDUFA date is August 22, 2026.

June 26 Capricor

Capricor presents positive five-year HOPE-2 OLE and HOPE-3 results

The data show durable skeletal and cardiac muscle benefit with a favorable safety profile over five years.

Media coverage

Yesterday BioSpace

Capricor CEO won’t rule out legal action against FDA after negative adcomm

After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior motive...

July 30 TMC

CAPR CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Capricor Therapeutics, Inc.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern...

July 30 Valdosta Daily Times

$CAPR Securities: Suffer Losses on Your Capricor Therapeutics Investment? BFA Law Notifies Investors of the ...

BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to...

July 30 GuruFocus

Capricor Therapeutics (CAPR) Faces FDA Advisory Setback Amid Challenging Valuation Landscape

In contrast, insider activity over ... insiders regarding near-term outlook or valuation. This divergence between guru accumulation and insider selling provides a nuanced perspective on...

Never miss news about Capricor

Track Capricor and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Capricor competitors & trending companies

Browse news for competitors to Capricor and other trending companies.